1. Introduction {#sec1}
===============

H~2~S is an important gasotransmitter as are nitric oxide, carbon monoxide, and ammonium \[[@B1]--[@B4]\]. Endogenous H~2~S is produced by three enzymes, cystathionine-*β*-synthase (CBS), cystathionine-*γ*-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase in conjunction with cysteine aminotransferase. In the brain, the production of H~2~S is mainly catalyzed by CBS \[[@B5]--[@B7]\].

H~2~S participates in the regulation of numerous physiological functions \[[@B8]\]. In the central nervous system (CNS), H~2~S exerts important multifaceted neuromodulatory effects. Evidence highlights a crucial role of H~2~S in the development of hypertension. For example, Yang et al. found that genetic deletion of CSE in mice resulted in hypertension \[[@B9]\]. Systemic administration of H~2~S donors and precursors decreased mean arterial pressure (MAP) in various models of hypertension \[[@B10]--[@B13]\]. Nevertheless, mediation of H~2~S in the cardiovascular center has been controversial \[[@B14]--[@B16]\].

The rostral ventrolateral medulla (RVLM), where sympathetic premotor neurons are located, is connected with other cardiovascular nuclei that regulate sympathetic nerve activity \[[@B17], [@B18]\]. Reactive oxygen species (ROS) in the RVLM plays a pivotal role in the pathogenesis of hypertension and heart failure \[[@B19]--[@B22]\]. Overproduction of O~2~ ^∙−^ and H~2~O~2~ contributes to hypertension by increasing sympathetic outflow to blood vessels \[[@B23]--[@B25]\]. Thus, upregulation of endogenous antioxidants is potentially an effective therapeutic strategy for cardiovascular diseases. A recent study indicates that neurons were protected by the antioxidant effect of H~2~S \[[@B26]\]. However, its role in central cardiovascular mechanisms remains unclear. The present study was undertaken to assess the hypothesis that H~2~S exerts antihypertensive effects by decreasing ROS production by inhibiting NADPH oxidase activity in the RVLM.

2. Materials and Methods {#sec2}
========================

2.1. Animals and Agents {#sec2.1}
-----------------------

Male spontaneously hypertensive rats (SHRs), weighing 280--310 g, were supplied by the Experimental Animal Center of Department of Physiology and Pathophysiology, Shanghai Medical College, Fudan University. They were housed socially (3--5 per cage with food and water ad libitum) and kept on a 12-hour light/12-hour dark cycle. Studies were approved by the Ethics Committee of Experimental Research, Shanghai Medical College, Fudan University. NaHS, lucigenin, S-adenosyl-l-methionine (SAM), and hydroxylamine hydrochloride (HA) were purchased from Sigma. Apocynin (APO) was purchased from Calbiochem, and the antibodies (anti-CBS, anti-MAP-2, anti-GFAP, and p47^phox^ antibodies) were purchased from Jackson and Abcom. BCA kits were purchased from Beyotime.

2.2. Immunofluorescence Staining and Laser Confocal Microscopy {#sec2.2}
--------------------------------------------------------------

Rats were anaesthetized with chloral hydrate (300 mg/kg ip) and then transcardially perfused with 150 mL saline followed by 250 mL 4% paraformaldehyde in 0.1 M sodium phosphate buffer (0.1 M PB; pH 7.4). Brains were rapidly dissected and postfixed in the same fixative solution at 4°C for 6 h and then transferred sequentially into 20 and 30% sucrose in 0.1 M PB for cryoprotection. Transverse serial medullary sections (30 *μ*m thick) were cut with a microtome (Reichert-Jung) 1.5--1.7 mm rostral to the obex according to Paxinos and Watson\'s atlas. Sections were immersed in 4% paraformaldehyde for 10 min followed by 6 × 5 min washing in 0.01 M phosphate-buffered saline (0.01 M PBS; pH 7.4). Free floating sections were incubated in 2% BSA and 0.2% Triton X-100 in 0.01 M PBS for 30 min at 37°C to eliminate nonspecific staining, and they were then exposed to antibodies for 1 h at 37°C, plus an additional 24 h at 4°C for the first primary antibody. The sections were then washed three times in TBST and incubated with fluorescent secondary antibodies for 60 min for confocal microscopy (Zeiss LSM510, Jena, Germany).

2.3. Microinjection into the RVLM {#sec2.3}
---------------------------------

Rats were anesthetized with a mixture of urethane (700 mg/kg) and *α*-chloralose (35 mg/kg) and intubated to facilitate ventilation. The left femoral artery was cannulated to monitor blood pressure and heart rate. Body temperature was maintained between 37°C and 37.5°C during the experiment with a temperature-controlled table. Then, rats were mounted in a stereotaxic frame and a micropipette tip (outer diameter 10--30 *μ*m) was inserted into the RVLM \[[@B27]\] for microinjection (1.8 to 2.1 mm lateral to the midline, 2.6 to 3.3 mm caudal to interaural line, and 0.3 to 0.9 mm from the ventral surface). Injection sites were confirmed histologically.

2.4. Intracerebroventricular Infusion {#sec2.4}
-------------------------------------

A lateral ventricular cannula was implanted after the general surgical procedures. Anesthetized rats were placed in a stereotaxic frame and a small hole was made in the skull (1.2--1.4 mm lateral to midline and 0.8--1.0 mm posterior to bregma). A 10 mm stainless steel guide cannula (22 gauges) was lowered 4 mm below the surface of the skull and fixed with cranioplastic cement. A stainless steel injector was introduced through the guide cannula to 0.5 mm beyond its tip.

2.5. Measurement of Superoxide Production {#sec2.5}
-----------------------------------------

The lucigenin-enhanced chemiluminescence assay was used to determine superoxide production as previously described \[[@B28]\]. After infusion of various agents, the ventrolateral medulla was removed and homogenized in a 0.02 mol/L phosphate-buffered saline (PBS), pH 7.4, containing 0.01 mM EDTA. The homogenate was centrifuged at 1000 g for 10 min at 4°C to remove nuclei and cell debris. Supernatant was obtained immediately for O~2~ ^∙−^ measurement. Background chemiluminescence was used for assessing O~2~ ^∙−^. An aliquot of supernatant (100 *μ*L) was then added to buffer (2 mL) containing lucigenin (5 *μ*mol/L) and measured for chemiluminescence. O~2~ ^∙−^ production was calculated and expressed as mean light unit per mg protein.

2.6. Measurement of NADPH Oxidase Activity {#sec2.6}
------------------------------------------

NADPH oxidase activity in the ventrolateral medulla was determined by a luminescence assay. The preparation was identical to that for O~2~ ^∙−^. The luminescent assay was performed in PBS buffer containing 0.01 M/L EGTA and 5 *μ*M/L lucigenin as the electron acceptor and 100 mM/L NADPH as the substrate. After dark adaptation, background counts were recorded and a tissue homogenate (1 *μ*L protein sample) was added. The chemiluminescence value was recorded at 1 min intervals for 30 min. O~2~ ^∙−^ production was measured after addition of NADPH to the incubation medium with and without a flavoprotein inhibitor of NADPH oxidase, Apocynin.

2.7. Western Blot Analysis {#sec2.7}
--------------------------

After having been anesthetized, rat medullas were rapidly removed and frozen immediately in liquid nitrogen until being homogenized in cell lysis buffer, followed by centrifugation at 12000 g for 15 min at 4°C. The supernatant was obtained for protein concentration. Then, protein samples were separated by 10% SDS-PAGE and transferred onto a nitrocellulose membrane. After blocking at room temperature in 5% BSA for 1 h, the membrane was incubated with various primary antibodies at 4°C overnight and then washed three times in TBST buffer and incubated with 1 : 5000 dilutions of anti-mouse IgG. Visualization was made with an enhanced chemiluminescent kit. Band densities on Western blot were quantified with *β*-actin as internal control.

2.8. Statistical Analysis {#sec2.8}
-------------------------

Data were analyzed with statistical software SigmaSTat (SPSS 17.0) and expressed as the mean ± SEM. One-way ANOVA with repeated measures was used as appropriate to assess group means followed by the Bonferroni post hoc tests. Probability values of *P* \< 0.05 were considered significant.

3. Results {#sec3}
==========

We studied H~2~S induced antihypertensive effects in SHRs by examining molecular mechanisms involved in the RVLM from 4 different aspects.

3.1. Expression of CBS {#sec3.1}
----------------------

Cellular distribution of CBS was identified by immunofluorescent stain coupled with laser confocal microscopy. CBS immunoreactivity was found in neuronal cells, but not in glia cells ([Figure 1](#fig1){ref-type="fig"}). CBS expressions in the RVLM were confirmed by Western blot assay, which were the same in SHRs and WKY rats at 8 weeks of age; however, expression was lower in SHRs at 17 weeks of age ([Figure 2](#fig2){ref-type="fig"}).

3.2. Effects of H~2~S on MAP and HR {#sec3.2}
-----------------------------------

Microinjection of NaHS (400 pmol/0.1 *μ*L) into the RVLM significantly decreased mean arterial blood pressure (MAP) and heart rate (HR) ([Figure 3](#fig3){ref-type="fig"}). Typically, MAP returned to baseline within 10--20 min. Similarly, microinjection of S-adenosyl-l-methionine (SAM, a CBS agonist, 10 pmol/0.1 *μ*L) or Apocynin (APO, a NADPH oxidase inhibitor, 10 nmo/0.1 *μ*L) decreased MAP. On the other hand, microinjection of hydroxylamine hydrochloride (HA, a CBS inhibitor, 9 nmol/0.1 *μ*L) increased MAP ([Figure 4](#fig4){ref-type="fig"}). These results support a link between H~2~S and ROS and provide novel evidence for regulation of hemodynamics by exogenous and endogenous H~2~S in the RVLM.

3.3. Effect of H~2~S on O~ 2 ~ ^∙−^ Production and NADPH Oxidase Activity {#sec3.3}
-------------------------------------------------------------------------

Microinjection of NaHS (400 pmol), SAM (10 pmol/0.1 *μ*L), APO (10 nmol/0.1 *μ*L), or Tempol (a SOD mimetic, 50 nmol/0.1 *μ*L) decreased the level of superoxide anion (O~2~ ^∙−^) in the RVLM ([Figure 5(a)](#fig5){ref-type="fig"}). NADPH oxidase is a major enzyme for superoxide production in the brain. To determine whether the decrease of ROS results from inhibition of this enzyme, we assessed the activity of NADPH oxidase and found that microinjection of NaHS, SAM, and APO decreased NADPH oxidase activity significantly ([Figure 5(b)](#fig5){ref-type="fig"}).

3.4. Effect of H~2~S on Phosphorylation of NADPH Oxidase {#sec3.4}
--------------------------------------------------------

Phosphorylation of p47^phox^ subunit is an important step for activation of NADPH oxidase. Thus, we examined the effect of intracerebroventricular infusion of NaHS on phosphorylation of p47^phox^ serine residues. We found that NaHS significantly decreased serine phosphorylation of p47^phox^ in the RVLM ([Figure 6](#fig6){ref-type="fig"}), supporting that NaHS reduces production of superoxide via suppression of serine phosphorylation of p47^phox^.

4. Discussion {#sec4}
=============

Our results provide the first evidence demonstrating that NADPH oxidase derived superoxide mediates the antihypertensive effects of H~2~S in the RVLM. Our statement is supported by the following 4 findings: (1) CBS was expressed in RVLM neurons, which provides an anatomical basis for the regulation; (2) increasing exogenous or endogenous H~2~S in the RVLM decreased NADPH oxidase activity, superoxide anion, and MAP; (3) decreasing ROS produced the same depressive effects; (4) infusion of NaHS inhibited phosphorylation of p47^phox^, a key step of NADPH oxidase activation.

H~2~S can be produced endogenously in various parts of the body in the heart, kidney, liver, and CNS. CBS is significantly expressed in the CNS, especially in the hippocampus and cerebellum, as well as the cerebral cortex and brain stem \[[@B29]\]. CBS has been identified in astrocytes, microglia, and neurons \[[@B30]--[@B32]\]. However, its cellular distribution in the RVLM is unknown. Our data revealed that CBS proteins were expressed mainly in RVLM neurons, but not glial cells ([Figure 1](#fig1){ref-type="fig"}). Furthermore, the level of CBS proteins in the RVLM was lower in SHRs than in WKY rats ([Figure 2](#fig2){ref-type="fig"}), which is consistent with a recent report of intracerebroventricular infusion with NaHS \[[@B33]\]. It is interesting to note that the difference in CBS expression did not occur until hypertension developed.

Accumulating evidence highlights the crucial role of H~2~S homeostasis in hypertension. A transient hypotensive effect was first reported in anesthetized rats with administration of H~2~S donors \[[@B4]\]. The CSE-L-cysteine pathway was downregulated and H~2~S was effective in reducing MAP and vascular remodeling in SHRs \[[@B12]\]. However, direct evidence for blood pressure control was reported in CES gene deficient mice \[[@B9]\]. Administration of H~2~S donors and precursors decreases MAP in various hypertensive models (chronic inhibition of nitric oxide synthase, two-kidney-one-clip, and SHRs) \[[@B9]--[@B13]\]. The antihypertensive effect of H~2~S has also been studied by infusion of NaHS into the RVLM cardiovascular center \[[@B15], [@B31]\]. The RVLM receives neuronal input from the paraventricular nucleus, solitary tracts nuclei, and so forth and then sends the signal to the spinal cord to regulate MAP and HR \[[@B17], [@B18]\]. Microinjection of NaHS (200, 400, and 800 pmol) into the RVLM decreases MAP, HR, and renal sympathetic nerve activity in a dose-dependent manner in SD rats \[[@B31]\]. Consistent with this study, our current results show that microinjection of NaHS (400 pmol) into the RVLM significantly decreased MAP and HR. Furthermore, we demonstrated that increased endogenous H~2~S by microinjection of SAM (a CBS agonist) or decreased ROS by infusion of Apocynin produced the same depressive effects, while microinjection of HA (a CBS inhibitor) increased MAP, supporting that H~2~S is a negative regulator for blood pressure in the RVLM.

Overproduction of ROS is critical for the pathogenesis of cardiovascular diseases, including hypertension and heart failure \[[@B21], [@B34], [@B35]\]. The baseline ROS, including O~2~ ^∙−^ and H~2~O~2~, in the RVLM is elevated in hypertensive animals \[[@B36], [@B37]\]. Elevated ROS in the brain increased MAP and sympathoexcitation, probably because of an upregulation of AT~1~ receptor and NADPH oxidase \[[@B38], [@B39]\]. It has been reported that NO exerts antihypertensive effects by inhibiting NADPH oxidase and thus reduces O~2~ ^∙−^ production \[[@B40]--[@B42]\]. Since H~2~S also exerts an antihypertensive effect, we speculate that H~2~S operates with the same mechanism. Indeed, exogenous (microinjection of NaHS) and endogenous (microinjection of SAM) H~2~S decreased NADPH oxidase activity and O~2~ ^∙−^ production. Our hypothesis is further supported by the decreased O~2~ ^∙−^ with the addition of Apocynin (a NADPH oxidase inhibitor) or Tempol (a cell membrane-permeable SOD mimetic). It is worth noting that increasing H~2~S by microinjection of NaHS or SAM decreased MAP and HR, while decreasing ROS by microinjection of Apocynin decreased MAP only. We speculate that H~2~S may exert additional influence on HR through another mechanism. Further studies are needed to verify this plausibility.

ROS can be produced by xanthine oxidase, cytochrome P450, mitochondrial respiratory chain enzyme, or NADPH oxidase, which is the major enzyme for superoxide production in the brain. Its activation is initiated by serine phosphorylation of its cytosolic regulatory p47^phox^ subunit \[[@B43], [@B44]\]. We found that NaHS infusion significantly decreased phosphorylated p47^phox^ levels in the RVLM, which would decrease enzyme activity of NADPH oxidase and superoxide production. Furthermore, microinjection of Apocynin decreased blood pressure. Muzaffar et al. observed that H~2~S downregulated NADPH oxidase and inhibited O~2~ ^∙−^ formation in pulmonary arterial endothelial cells, and this effect could be canceled by inhibitors of PKA, but not by inhibitors of PKG, indicating that the effect of H~2~S on NADPH oxidase may be mediated by the adenylyl cyclase-cAMP-PKA pathway \[[@B45]\]. Taken together, our results suggest that NADPH oxidase-derived superoxide mediates H~2~S induced central depressive effects. Since NADPH oxidase is composed of membrane-bound (gp91^phox^ and p22^phox^) and cytoplasmic (p47^phox^, p40^phox^, and p67^phox^) subunits and small molecules (GTPase Rac1 and/or Rac2), the role of each component of the enzyme in the mediation requires further exploration.

In summary, present studies demonstrated that the H~2~S metabolic system was present in the RVLM, and central administration of H~2~S into the RVLM decreased phosphorylation of NADPH oxidase, NADPH oxidase activity, and O~2~ ^∙−^ production and reduced MAP and HR in SHRs, whereas decreasing H~2~S by microinjection of a CBS antagonist increased MAP. Yet our data support that H~2~S in the RVLM may decrease MAP mediated through NADPH oxidase, which is largely based on correlation, and a direct mediation is not conclusive. Further studies are still needed. Nevertheless, since overproduction of superoxide in the CNS is involved in the etiology of hypertension, we expect that the H~2~S-NADPH oxidase-superoxide system may be an effective therapeutic target in preventing hypertension.
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![CBS expression in RVLM neurons. Confocal images showed that CBS immunoreactivity is colocalized with a neuronal marker (MAP2: upper panels) but not a glia marker (GFAP: lower panels).](OMCL2015-927686.001){#fig1}

![CBS is expressed less in the RVLM of hypertensive rats. CBS protein expression in WKY rats (*n* = 5) and SHR (*n* = 6) at 8 weeks (a) and 17 weeks (b). ^\*^ *P* \< 0.05, SHR versus WKY. Please note that the difference in CBS expression occurred only at 17 weeks of age, when hypertension developed.](OMCL2015-927686.002){#fig2}

![Microinjection of NaHS (400 pmol) into the RVLM decreased MAP and HR in SHRs. (a) Typical MAP and HR traces in response to the microinjection. (b) Maximal changes detected during the response. (c) Time courses of MAP and HR in response to microinjections of aCSF, artificial cerebral spinal fluid (*n* = 5), or NaHS (*n* = 4). ^\*^ *P* \< 0.05 versus aCSF control group.](OMCL2015-927686.003){#fig3}

![Maximal responses in MAP (a) and HR (b) to microinjections of different agents into the RVLM in SHRs. aCSF (control), *n* = 5; NaHS (H~2~S donor), *n* = 7; SAM (a CBS agonist), *n* = 5; HA (a CBS inhibitor), *n* = 5; and APO (NADPH oxidase inhibitor), *n* = 5. ^\*^ *P* \< 0.05 versus aCSF group.](OMCL2015-927686.004){#fig4}

![Infusion of various depressive agents suppressed NADPH oxidase activity and superoxide production in the RVLM of SHRs. Tissue levels of superoxide anion (a) and NADPH oxidase activity (b) after infusion of aCSF (artificial cerebral spinal fluid, *n* = 9), NaHS (H~2~S donor, *n* = 5), Apocynin (NADPH oxidase inhibitor, *n* = 5), SAM (a CBS agonist, *n* = 4), or Tempol (SOD mimetic, *n* = 4). ^\*^ *P* \< 0.05 versus aCSF group.](OMCL2015-927686.005){#fig5}

![Exogenous H~2~S suppressed p47^phox^ phosphorylation of NADPH oxidase in the RVLM. Western blots show that p47^phox^ phosphorylated/p-47 protein levels after intracerebroventricular infusion of aCSF or NaHS. Representative gel: (a) representative densitometric analysis and (b) group data (*n* = 5); ^\*^ *P* \< 0.05 versus aCSF group.](OMCL2015-927686.006){#fig6}
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